anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention relates to solid drink for controlling primary hypertension. Raw haw slices and Kwang-Ti-lung are used as main raw materials, are matched with salvia, ginseng, bee pollen, white sugar and dextrin, and are concentrated into wet paste with the specific weight of 1 to 2 after the present invention carries out washing, immersion, boiling, filtration, depressurized concentration, hanging deposition and ethyl alcohol recovery. The wet paste is processed into granular instant solid drink. The present invention can use tea to replace medicine, and have the advantages of convenient taking, cheap cost, no containing of any preservative and hormone, crisp mouth feeling, sour and sweet feeling and no any side effect. Patients take the present invention twice per day, and use one to two packages every time. After the present invention is used for two to six months, the primary hypertension in early and middle periods can be controlled.
The safety and efficacy of OXYCODONE HCl EXTENDED-RELEASE TABLETS have been established in pediatric patients ages 11 to 16 years. Use of OXYCODONE HCl EXTENDED-RELEASE TABLETS is supported by evidence from adequate and well-controlled trials with OXYCODONE HCl EXTENDED-RELEASE TABLETS in adults as well as an open-label study in pediatric patients ages 6 to 16 years. However, there were insufficient numbers of patients less than 11 years of age enrolled in this study to establish the safety of the product in this age group. 

The safety of OXYCODONE HCl EXTENDED-RELEASE TABLETS in pediatric patients was evaluated in 155 patients previously receiving and tolerating opioids for at least 5 consecutive days with a minimum of 20 mg per day of oxycodone or its equivalent on the two days immediately preceding dosing with OXYCODONE HCl EXTENDED-RELEASE TABLETS. Patients were started on a total daily dose ranging between 20 mg and 100 mg depending on prior opioid dose.

The most frequent adverse events observed in pediatric patients were vomiting, nausea, headache, pyrexia, and constipation [see Dosage and Administration (2.5), Adverse Reactions (6.1), Clinical Pharmacology (12.3) and Clinical Studies (14)].
Bladder cancer is the fourth most common malignancy in men and the ninth most common in women in the US, with an estimated 68,810 new cases and 14,070 deaths for the year 2008. Approximately 90% to 95% of newly diagnosed patients are with transitional cell carcinomas (TCC). Approximately 20% to 25% contain advanced (muscle invasive or metastatic) disease. Muscle invasive bladder cancer is life threatening. Clinical trials have demonstrated that TCC is a chemotherapy-sensitive malignancy. Most current cancer treatment strategies involve the use of chemotherapeutic or biological drugs that have a low therapeutic ratio. The limitations are a consequence of effects of the therapeutic drug on normal tissues. One approach to control systemic exposure effects is to target the drug itself into the site of the tumor. For example, antibodies have been developed for use as tumor targeting agents and have had success in the clinic. However, despite the promise of antibody-based immunotherapy, there are limitations with these class of reagents. Even so, immunotherapy remains a promising approach to treat cancer.

One strategy that has received attention is treatment with cytokines such as IL-2 to enhance anti-tumor immunity. IL-2 has stimulatory effects on a number of immune cell types including T and B cells, monocytes, macrophages, lymphokine-activated killer cells (LAK) and natural killer (NK) cells. Based on the ability of IL-2 to provide durable curative anti-tumor responses, systemic administration of IL-2 has been approved to treat patients with metastatic melanoma or renal carcinoma. Unfortunately, the considerable toxicity associated with this treatment makes it difficult to achieve an effective dose at the site of the tumor and limits the population that can be treated. Thus, there is critical need for innovative strategies that enhance the effects of IL-2, to reduce its toxicity without compromising the clinical benefit, and to treat other diagnoses.

The study drug, ALT-801, is a biologic compound of interleukin-2 (IL-2) genetically fused to a humanized soluble T-cell receptor directed against the p53-derived peptides expressed on tumor cells. The p53 protein is one of the most important factors that protects from developing cancer and is also one of the most frequently mutated genes in many cancers, which include muscle-invasive bladder cancer. For any given cancer type, p53 dysfunction generally correlates with poor prognosis versus other the same site-of-origin. In some tumors, p53 mutation and over-expression also is associated with resistance to chemotherapy. This study is to further evaluate whether directing IL-2 activity using ALT-801 to the patient's tumor sites that over-express p53 results in clinical benefits
PROBLEM TO BE SOLVED: To provide a SOD(superoxide dismutase)-like extract composition containing a coffee bean extract, having a safe excellent SOD action, and exhibiting the effect even in a small amount. SOLUTION: This SOD-like extract composition contains 0.0005-5 wt.% of a coffee bean extract extracted from coffee beans. The SOD-like extract composition is forcibly orally administered into rat through stomach tubes, and the SOD activity and the peroxidized lipid concentration in the bodies are measured from the obtained blood samples. Consequently, the SOD activities of all test groups are higher than those of control groups, and a significant difference therebetween is thereby recognized. It is also recognized that the concentrations of peroxidized lipids are significantly lower than those of the control groups. The SOD-like extract composition thereby shows to exhibit the actions in vivo by the oral administration and further significantly enhance the active oxygen- eliminating ability of the bodies even in small amounts.
The present invention discloses a pure Chinese patent medicine for treating chronic coryza, pharyngitis and globus hysteritis diseases. The present invention is prepared from the raw materials including sweet wormwood herb, baical skullcap root, tuckahoe, dried orange peel, orange fruit, talc, raw licorice, bamboo shaving, trichosanthes, fritillaria, peach seed, clematis root, Codonopsis pilosula, reed rhizome and biond magnolia flower. The medicine of the present invention has the functions of clearing heat, dissipating phlegm, promoting qi, relieving stagnation, eliminating stasis for stopping pain, relieving sore-throat for restoring voice, eliminating pus, treating anthracia, promoting blood circulation, removing blood stasis, loosening bowels and relieving constipation. The medicine treats both the manifestations and the root causes of diseases, has rapid medicine potency, and directly acts on the disease focuses. The present invention has the advantages of significant therapeutic effect without toxic or side effect and low cost. The pure Chinese patent medicine can eliminate risk factors which cause the occurrence and the development of chronic coryza, pharyngitis and globus hysteritis diseases as soon as possible, alleviate pain for patients who suffer from chronic coryza, pharyngitis and globus hysteritis diseases for a long time, and prevent chronic pharyngitis and globus hysteritis diseases from being deteriorated into cancer. The buccal administration of the formula whose all medicines are mutually matched can rapidly control and rapidly treat the stubborn symptoms of chronic coryza and pharyngitis.
Despite increasing knowledge of disease-causing genes in human genetics, approximately half of the individuals affected by neurodevelopmental disorders remain genetically undiagnosed. Part of this missing heritability might be caused by genetic variants outside of protein-coding genes, which are not routinely diagnostically investigated. A recent preprint identified de novo variants in the non-coding spliceosomal snRNA gene RNU4-2 as a cause of a frequent novel syndromic neurodevelopmental disorder. Here we mined 164 whole genome sequencing (WGS) trios from individuals with neurodevelopmental or multiple congenital anomaly disorders that received diagnostic genomic investigations at our clinic. We identify a recurrent de novo RNU4-2 variant (NR_003137.2(RNU4-2):n.64_65insT) in a 5-year-old girl with severe global developmental delay, hypotonia, microcephaly, and seizures that likely explains her phenotype, given that extensive previous genetic investigations failed to identify an alternative cause. We present detailed phenotyping of the individual obtained during a 5-year follow-up. This includes photographs showing recognizable facial features for this novel disorder, which might allow prioritizing other currently unexplained affected individuals sharing similar facial features for targeted investigations of RNU4-2. This case illustrates the power of re-analysis to solve previously unexplained cases even when a diagnostic genome remains negative.
BACKGROUND: Hidradenitis suppurativa (HS) is a chronic inflammatory disorder associated with tunnel formation and scarring. Surgical excision is a potential curative therapy for HS.
OBJECTIVES: To characterize the surgical outcomes of patients with HS undergoing complete excision and to identify the risk factors associated with postoperative recurrence.
METHODS: This retrospective 16-year cohort study enrolled patients ≥ 20 years who underwent complete excision for HS lesions at the National Taiwan University Hospital. We assessed the rates of postsurgical recurrence and complications and estimated the odds ratio (ORs) with 95% confidence intervals (CIs) of their association with potential risk factors using generalized estimating equations.
RESULTS: In total, 136 patients with HS and the 284 corresponding complete excisions were identified. Recurrence developed in 88 of 284 (31.0%) operations and complications occurred in 102 (35.9%). Common types of complications included wound dehiscence, hypertrophic scars and surgical-site infection. Clinical factors associated with a lower risk of recurrence were male sex [adjusted OR (aOR) 0.48, 95% CI 0.23-0.98], surgery at atypical body sites (aOR 0.28, 95% CI 0.08-0.99) and wound repair by split-thickness skin graft (aOR 0.31, 95% CI 0.12-0.77). Wound dehiscence was associated with an increased risk of recurrence (aOR 2.55, 95% CI 1.21-5.42). No independent factors were identified as being associated with composite postoperative complications.
CONCLUSIONS: Complete excision alone can be effective in curing HS in Asian populations. Recurrence developed in about one-third of the complete excisions performed for HS. Sex, surgical body sites, methods of wound repair and wound dehiscence were major determinants for recurrence.
Method for predicting sensitivity of a patient suffering from cancer to DNA methylation inhibitor therapy uses in vitro in cancer cells taken from the patient. Cells are compared with parent type cells for expression of bromodomain containing genes, of other listed genes, and/or of bromodomain containing proteins. Mutations involving the amino acid sequence of bromodomain containing genes and/or mutations involving non-synonymous change in amino acid sequence of other genes may be examined. The half maximal inhibitory concentration (IC50) of inhibitors of DNA methyltransferase, histone acetyltransferase, histone methyltransferase, histone deacetylases, and/or histone demethylases are determined. Increase in (IC50) signifies cross-resistance. The half maximal inhibitory concentration (IC50) of a selective BET bromodomain inhibitor is also determined, wherein decrease in the (IC50) signifies sensitivity. A combination therapy for cancers using bromodomain inhibitors in combination with DNA methylation inhibitors is also provided.
In this enteric capsule with oil coating, powdered or garrulous contents meant to fill the capsule is mixed with a dose of ester containing sesaminol triglucosides or coixenolide. With the feature that emulsification arises while ester containing Sesaminol Triglucosides or coixenolide is integrated with the bile in human body, so that the activity of pharmacological molecules can be prevented, the pharmacological molecules of the contents is able to be coated by ester, forming carriers which are the ester oil film protecting the pharmacological activity of small molecules and ensuring that they can be transported to the small intestine. In this way, the capsule will prevent the pharmacological molecules of the contests from being decomposed by gastric acid when the capsule passes through it. Before entering the small intestine, with the emulsification brought about by the combination of ester oil film and bile, the pharmacological molecules of the contents can remain active for the optimum pharmacological activity after their entrance into the small intestine, decomposition, emulsification, and transportation into the blood. The absorptivity of the capsule will be enhanced when it is consumed. As a consequence, chances that the consumption of the capsule with pharmacological molecules causes the irritation of stomach will be effectively reduced, and stomach health will be protected.
A prod. for treating the female bust contain tissue extracts obtd., by Filatov's method and also phytostimulines extracted from plants by Filatov's method. The revitalising and tissue-firming effect is increased by the phyto-stimulines. The prod. doest no affect the adjacent adipose tissue or the mammary gland. The prod. may also contain plant extracts which have strong astringent action and stimulate local blood circulation. Pref., the compsn. contains an astringent film-forming agent which promotes and accelerates the action of the compsn.
The study is designed as a prospectively enrolling, quasi-experimental cohort study in cancer patients, eligible for systemic treatment.

The CAPABLE cohort will receive the smartphone application and a multi-sensorial smartwatch (ASUS VivoWatch 5 HC-B05). Patients will be asked to use the system for at least 6 months after enrollment. If, after 6 months, a patient wants to keep using the system, he will be allowed to do so, until the end of the study. Questionnaires on health-related quality of life will be administered to the patients on baseline (T0) and every three months (T1 and T2). Lost to follow-up data will be included in intention-to-treat analysis. Qualitative and quantitative user experience studies will be done at enrollment, after 3 months and at the end of the follow-up period with the CAPABLE system. Results of this interventional study will be compared with a control cohort consisting of renal cell carcinoma patients, recruited in 2021 with the same inclusion criteria as this study population, but receiving standard care (ICSM CE number 2546, dated 13/04/2021 and amended on 09/02/2022).
The invention comprises a substance having maxima in the U.V absorption spectra, when dissolved in ethanol, at 242 mm  and 259 mm , and being the product obtained by reduction with an alkali metal and an alcohol of the U.V. irradiation product of 7-dehydrocholesterol or an ester thereof and the preparation thereof. Sodium may be used as alkali metal.  As the alcohol there may be used ethanol, propanol, propanol-2, butanol, 2-methyl butanol-2, ethane diol-1,2 and propane-diol-1,3.  Reaction may be effected at 70-140 DEG  C.  Examples describe the reduction of Vitamin D3 and of a product obtained by irradiating 7-dehydrocholesterol.ALSO:A product obtained by reduction with an alkali metal and an alcohol of the U.V. irradiation product of 7-dehydrocholesterol or an ester thereof, can be employed in aqueous dispersions or solutions for increasing the calcium content of the blood of animals.  Additives, e.g. NaCl and glycerine, may be employed to obtain solutions isotonic with blood.
Obesity disproportionately affects Latinx communities and is linked to an increased risk of mental health problems. Military veterans are more likely to develop mental health problems, but the role of Latinx ethnicity in moderating the association between obesity and these problems is unclear. To address this gap, this study examined psychiatric and psychosocial correlates of obesity in a nationally representative sample of Latinx and White U.S. military veterans. Data were analyzed from the 2019-2020 National Health and Resilience in Veterans Study, which surveyed 3524 Latinx and White veterans. Analyses revealed that Latinx ethnicity moderated associations between obesity and several measures. Specifically, among veterans with obesity, Latinx veterans had higher rates of major depression, generalized anxiety, post-traumatic stress disorders, drug use disorders, non-suicidal self-injury, and higher levels of childhood trauma, loneliness, and hostility relative to White veterans. These findings underscore the importance of culturally sensitive prevention and treatment efforts to help mitigate symptoms of internalizing disorders, drug use disorder, loneliness, and hostility, and to cultivate psychosocial resources such as resilience and coping self-efficacy among Latinx veterans with obesity.
<P>PROBLEM TO BE SOLVED: To provide a method of making up eyelashes, in which beautifully finished eyelashes can be formed by efficiently exhibiting a shrinking function of eyelash cosmetics having physical properties of shrinking by drying, so as to be able to effectively curl the entire eyelashes including the hair tips.  <P>SOLUTION: The method of making up eyelashes includes an application process of applying, from above the eyelashes, the eyelash cosmetics having physical properties of shrinking by drying and a holding-up process of holding up the eyelashes. The holding-up process can be performed after or simultaneously with the application process. The holding-up process is desirably performed by using a cosmetic tool that has a function of holding up the eyelashes from below. It is desirable that the application process and the holding-up process are performed after the eyelashes are coated with mascara.  <P>COPYRIGHT: (C)2009,JPO&INPIT
Disclosed are methods for determining copy number variation (CNV) known or suspected to be associated with a variety of medical conditions. In some embodiments, methods are provided for determining copy number variation (CNV) of fetuses using maternal samples comprising maternal and fetal cell free DNA. In some embodiments, methods are provided for determining CNVs known or suspected to be associated with a variety of medical conditions. Some embodiments disclosed herein provide methods to improve the sensitivity and/or specificity of sequence data analysis by removing within-sample GC-content bias. In some embodiments, removal of within-sample GC-content bias is based on sequence data corrected for systematic variation common across unaffected training samples. Also disclosed are systems and computer program products for evaluation of CNV of sequences of interest.
The investigators adopt Noninvasive Positive Pressure Ventilation for weaning in tracheotomy patients innovatively .If patients'conditions met our defined criterions, the investigators randomly allocate two groups. One group adopts traditional weaning strategy, the other adopts Noninvasive Positive Pressure Ventilation. If patients' condition deteriorated in group two, the investigators turned them to invasive positive pressure ventilation, until patients adapted in a satisfactory condition, the investigators shift them into Noninvasive Positive Pressure Ventilation. The investigators will extubate the tracheotomy tube, if patients are received Noninvasive Positive Pressure Ventilation more than 24 to 48 hours. After extubation, the investigators try to wean Noninvasive Positive Pressure Ventilation. Successful wean is defined weaning mechanical ventilation more than 48 hours.
Inherited defects in the genes of blood coagulation essentially express the severity of the clinical phenotype that is directly correlated to the number of mutated alleles of the candidate leader gene (e.g., heterozygote vs. homozygote) and of possible additional coinherited traits. The F5 gene, which codes for coagulation factor V (FV), plays a two-faced role in the coagulation cascade, exhibiting both procoagulant and anticoagulant functions. Thus, defects in this gene can be predisposed to either bleeding or thrombosis. A Sanger sequence analysis detected a premature stop-codon in exon 13 of the F5 gene (c.3481C>T; p.R1161Ter) in several members of a family characterised by low circulating FV levels and contrasting clinical phenotypes. The propositus, a 29 y.o. male affected by recurrent haemorrhages, was homozygous for the F5 stop-codon and for the F5 c.1691G>A (p.R506Q; FV-Leiden) inherited from the heterozygous parents, which is suggestive of combined cis-segregation. The homozygous condition of the stop-codon completely abolished the F5 gene expression in the propositus (FV:Ag < 1%; FV:C < 1%; assessed by ELISA and PT-based one-stage clotting assay respectively), removing, in turn, any chance for FV-Leiden to act as a prothrombotic molecule. His father (57 y.o.), characterised by severe recurrent venous thromboses, underwent a complete molecular thrombophilic screening, revealing a heterozygous F2 G20210A defect, while his mother (56 y.o.), who was negative for further common coagulation defects, reported fully asymptomatic anamnesis. To dissect these conflicting phenotypes, we performed the ProC®Global (Siemens Helthineers) coagulation test aimed at assessing the global pro- and anticoagulant balance of each family member, investigating the responses to the activated protein C (APC) by means of an APC-sensitivity ratio (APC-sr). The propositus had an unexpectedly poor response to APC (APC-sr: 1.09; n.v. > 2.25), and his father and mother had an APC-sr of 1.5 and 2.0, respectively. Although ProC®Global prevalently detects the anticoagulant side of FV, the exceptionally low APC-sr of the propositus and his discordant severe-moderate haemorrhagic phenotype could suggest a residual expression of mutated FV p.506QQ through a natural readthrough or possible alternative splicing mechanisms. The coagulation pathway may be physiologically rebalanced through natural and induced strategies, and the described insights might be able to track the design of novel treatment approaches and rebalancing molecules.
Total knee Arthroplasty is a common operated surgery in each hospitals, and a lots of patients benefit from this surgery. Traditionally the frequently used surgical approach is parapatellar approach. However, recently the subvastus and midvastus approach has gained a world-wide population. These two methods had less damage to the quadriceps tendon and theoretically should have better post-operative muscle power recovery, less lateral retinaculum release because of better patellar tracking. The only differences between these two approaches are that the midvastus approach will split the vastus medialis muscle and denervation may occur. In this study we will use HSS or KSS functional score and Cybex dynamometer to evaluate the functional recovery, and use Merchant's view radiography to evaluate the result of patellar tracking. The follow-up period will not be limited and we will use mixed-model statistic's random effect to gain the natural history of muscle power recovery, which will become the base of other study. We can also compare the difference of results between PS type and CR type and different surgical approach. The natural history of the knee score will also be obtained.